NK Research and Charts

NK - NantKwest Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-05-01)

Last 2.49	Change ⇓ -0.02 (-0.80%)	Volume 3,132,866
	Open 2.54	High 2.54	Low 2.43

8EMA (Daily) 2.56	40EMA (Daily) 2.77	50EMA (Daily) 2.83	STO (Daily) 26.726	MACD Hist (Daily) -0.008
8EMA (Weekly) 2.722	40EMA (Weekly) 3.56	50EMA (Weekly) 3.70	STO (Weekly) 15.121	MACD Hist (Weekly) -0.044


Company Profile
NantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The company's drug candidates such as activated NK cells, high-affinity NKs and target activated NK's address virally-induced cancers, viral, fungal and bacterial infections as well as critical diseases such as Ebola. Its pipeline product includes taNK, haNK, and aNK. Most of NatWest's sales are concentrated in the United States region although it has a reasonable market in Europe and other Non-U.S territories.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.